James Simsarian

Factors that influence adherence with disease-modifying therapy in MS

Katherine Treadaway, Gary Cutter, Amber Salter et al. · Journal of Neurology · 2009 · 257 citations

Disease Management, Chronic Disease Management, Patient Support +2

Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

Gavin Giovannoni, F. Casset‐Semanaz, John King et al. · Multiple Sclerosis Journal · 2008 · 68 citations

The utility of computerized neuropsychological assessment of cognitive dysfunction in patients with relapsing-remitting multiple sclerosis

Jeffrey Wilken, Robert L Kane, Cynthia Sullivan et al. · Multiple Sclerosis Journal · 2003 · 68 citations

Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif (R) new formulation) in a phase IIIb study in patients with relapsing multiple sclerosis: 96-week results

James Simsarian, О. Л. Барбараш, F. Casset‐Semanaz et al. · 2008 · 44 citations

Clinical Immunology, New Formulation, Autoimmune Disease +10

Immunogenicity and tolerability of an investigational formulation of interferon-β1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis

Gavin Giovannoni, Florence Casset‐Semanaz, Amer Jaber et al. · Clinical Therapeutics · 2007 · 42 citations

Clinical Immunology, 48-Week Interim Analyses, Autoimmune Disease +12